SBIOALPS Medical Breakthroughs ETF

Grow my money11y track recordRanked #1,091 of 2,960 in this goal

Seeks investment results that correspond to the performance of the S-Network Medical Breakthroughs Index.

By ALPS · Launched 2014

Annual Cost

0.50%

#2,576 of 5,562 · average

Fund Size

$162M

#2,483 of 5,562 · mid-size

Return (1Y)Goal

+81.8%

Track Record

11 years

#1,261 of 5,562 · established

Performance

Total-return NAV · USD

Growth of $10,000

$18,968+89.7%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

Global

Cap

Smid

Strategy

Index tracking

Sector

Health care

Focus

Biotech & Genomics

Index tracked

S-Network Medical Breakthroughs Index

What it actually holds

By weight

Concentration

Top 10 holdings = 31.4% of fund✓ well diversified

Avidity Biosciences Inc

4.5%

Cytokinetics Inc

3.4%

Axsome Therapeutics Inc

3.3%

Rhythm Pharmaceuticals Inc

3.2%

Arrowhead Pharmaceuticals Inc

3.0%

Merus Nv

3.0%

Nuvalent Inc

3.0%

Ptc Therapeutics Inc

2.8%

Vaxcyte Inc

2.7%

Krystal Biotech Inc

2.6%

Asset allocation

Stocks

100.0%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

29.8%High

Year-on-year price swings

Max drawdown

-63.1%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.62Decent risk-adjusted returns

Sortino (3Y)

0.90Moderate downside risk

Where to buy

Listing

Exchange: NYSE Arca

Full fund details

Objective: Seeks investment results that correspond to the performance of the S-Network Medical Breakthroughs Index.
Strategy: Employs a passive management approach designed to track the performance of the S-Network Medical Breakthroughs Index, which includes small and mid-cap biotechnology stocks with drugs in Phase II or III FDA trials. Invests at least 80% of net assets in index securities.
Inception date: December 30, 2014
Fund family: ALPS